Back to Search
Start Over
Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis.
- Source :
- Journal of the American Academy of Dermatology; May2009, Vol. 60 Issue 5, p781-785, 5p
- Publication Year :
- 2009
-
Abstract
- <bold>Background: </bold>Thrombocytopenia has been reported to be associated with efalizumab therapy, but has only sporadically been reported with other anti-tumor necrosis factor alfa (TNF-alpha) agents.<bold>Objective: </bold>To describe the frequency of thrombocytopenia in a cohort of patients who underwent biological therapies for psoriasis.<bold>Methods: </bold>This was a retrospective observational study of 93 patients.<bold>Results: </bold>One hundred eighteen courses of biological therapies were administered to 93 patients. Four of 67 patients who received anti-TNF-alpha agents developed drug-induced thrombocytopenia during treatment, compared with none of the 51 patients receiving efalizumab therapy. The platelet count recovered after suspension of anti-TNF-alpha agents in 3 patients and relapsed after re-exposure in two patients. The overall estimated frequency of thrombocytopenia in our cohort was 4.30% (95% confidence interval [CI], 0% to 6.2%).<bold>Limitations: </bold>These findings should be validated in larger studies.<bold>Conclusions: </bold>Drug-induced thrombocytopenia is a potential side effect of anti-TNF-alpha agents. Immediate monitoring of platelet counts is recommended if autoimmunity is suspected. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01909622
- Volume :
- 60
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- Journal of the American Academy of Dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 105511691
- Full Text :
- https://doi.org/10.1016/j.jaad.2008.12.001